Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating loncastuximab tesirine for relapsed or refractory diffuse large B-cell lymphoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Loncastuximab tesirine (loncastuximab tesirine)

Snippet

Sponsor: ADC Therapeutics S.A. | Conditions: Diffuse Large B-Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent | Phase 2 | Status: COMPLETED | Results posted: 2021-07-29